INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
INVO Fertility (Nasdaq: IVF) reported third-quarter 2026 revenue growth of 26%, supported by existing clinics and contributions from acquired practices. Revenue reached $2,222,656, while clinic revenue rose 28% to $2,207,587. Net loss narrowed to $2,149,920 from $3,395,598 a year earlier, and operating loss narrowed to $1,477,360 from $1,635,484.
Clinic-Level Adjusted EBITDA, a non-GAAP earnings measure before corporate expenses, increased to $292,114 from $243,120, marking its seventh consecutive positive quarter. It excludes a $192,932 Birmingham acquisition-transition adjustment. Consolidated Adjusted EBITDA worsened to negative $1.0 million from negative $0.9 million. Cash reached $3,695,770 at September 30, compared with $2,077,842 at year-end 2025; current liabilities fell to approximately $4.5 million from $10.3 million. Nine-month net loss narrowed, but the loss from continuing operations widened.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 revenue increased 26% to $2,222,656 from $1,757,094 a year earlier.
- Moderate pointQ3 net loss narrowed to $2,149,920 from $3,395,598; loss per share improved to $2.44 from $157.43.
- Moderate pointQ3 Clinic-Level Adjusted EBITDA rose to $292,114 from $243,120, its seventh consecutive positive quarter before corporate expenses.
- Moderate pointCash increased to $3,695,770 at September 30, 2026, from $2,077,842 at December 31, 2025.
- Moderate pointCurrent liabilities declined to approximately $4.5 million from $10.3 million at year-end 2025.
- Moderate pointBirmingham's remaining 50% interest was acquired in June 2026, completing full ownership.
- Moderate pointNine-month net loss narrowed to $6,800,531 from $24,418,153, which included discontinued-operation losses.
16 minor points
- Minor pointQ3 clinic revenue increased 28% to $2,207,587 from $1,722,223 a year earlier.
- Minor pointQ3 operating loss narrowed to $1,477,360 from $1,635,484 a year earlier.
- Minor pointTotal assets increased to $25,500,200 from $20,220,124 at year-end 2025.
- Minor pointTotal liabilities declined $5.5 million from year-end 2025; net equity reached $18.0 million.
- Minor pointWisconsin and Atlanta clinics recorded revenue growth; Indiana and Birmingham each contributed a full quarter.
- Minor point. Forward-looking: it has not happened yet and may not happen.Birmingham investment plans include recruiting a new physician and adding services.
- Minor pointQ3 selling, general and administrative expenses fell to $2,071,438 from $2,128,088.
- Minor pointQ3 interest expense fell to $154,768 from $322,765; interest income reached $74,735 from zero.
- Minor pointQ3 debt-extinguishment loss was zero, compared with $1,416,610 a year earlier.
- Minor pointNine-month revenue rose to $6,413,366 from $5,257,933, including clinic revenue of $6,357,605 versus $5,175,870.
- Minor pointNine-month operating loss narrowed to $4,357,981 from $5,825,100.
- Minor pointNine-month impairment loss was zero, versus $1,397,353; depreciation and amortization fell to $465,835 from $540,940.
- Minor pointNine-month debt-extinguishment loss fell to $172,621 from $2,108,880.
- Minor pointNine-month interest expense fell to $512,318 from $1,071,200; interest income reached $214,249 from zero.
- Minor pointNine-month remeasurement gain totaled $2,452,032, versus zero a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Management plans to expand through established, profitable clinic acquisitions and improve existing clinic operations.
Negative
- Major pointNine-month derivative valuation shifted to a $4,353,222 loss from a $1,626,594 gain. 1.4× market cap
- Moderate pointQ3 consolidated Adjusted EBITDA worsened to negative $1.0 million from negative $0.9 million.
- Moderate pointBirmingham acquisition consideration was $175,001 payable to sellers for the remaining 50% interest. 5.6% of market cap
- Moderate pointQ3 service costs increased to $1,436,870 from $1,121,174 across the expanded clinic network.
- Moderate pointQ3 derivative fair-value loss increased to $562,997 from $33,566. 18% of market cap
- Moderate pointNine-month continuing-operations loss widened to $6,800,531 from $6,431,074.
12 minor points
- Minor pointQ3 clinic segment profit fell to $62,909 from $129,689.
- Minor pointBirmingham transition reduced Q3 clinic contribution by approximately $193,000 through revenue disruption and increased physician-transition costs.
- Minor pointQ3 product revenue fell to $15,069 from $34,871, partly reflecting eliminated intercompany sales.
- Minor pointQ3 cost of goods sold increased to $14,144 from $6,575.
- Minor pointQ3 depreciation and amortization increased to $177,564 from $136,741.
- Minor pointQ3 income-tax provision reached $29,530, versus zero a year earlier.
- Minor pointNine-month product revenue fell to $55,761 from $82,063.
- Minor pointNine-month service costs rose to $4,071,782 from $3,252,659.
- Minor pointNine-month cost of goods sold rose to $79,443 from $13,622.
- Minor pointNine-month selling, general and administrative expenses rose to $6,154,287 from $5,878,459.
- Minor pointNine-month income-tax provision reached $85,684, versus zero a year earlier.
- Minor pointNine-month settlement gain was zero, compared with $939,500 a year earlier.
News Explained
The balance sheet lists 119,358 common shares outstanding at
Key Figures
- Revenue
- $2,222,656, up 26%
- Q3 2026 vs. $1,757,094 in Q3 2025
- Consolidated clinic revenue
- $2,207,587, up 28%
- Q3 2026 vs. $1,722,223 in Q3 2025
- Net loss
- $(2,149,920)
- Q3 2026 vs. $(3,395,598) in Q3 2025
- Loss from operations
- $(1,477,360)
- Q3 2026 vs. $(1,635,484) in Q3 2025
- Clinic-Level Adjusted EBITDA
- $292,114
- Q3 2026 vs. $243,120 in Q3 2025; before corporate expenses
- Consolidated Adjusted EBITDA
- $(1.0) million
- Q3 2026 vs. $(0.9) million in Q3 2025
- Cash and current liabilities
- $3.7 million cash; $4.5 million current liabilities
- At September 30, 2026; compared with $2.1 million and $10.3 million at December 31, 2025
Previous Earnings Reports
-
Reported revenue growth and positive clinic-level EBITDA, establishing the preceding operating baseline.
-
Reported clinic revenue growth alongside a net loss in the comparable prior-year quarter.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
in vitro fertilization medical
non-gaap financial measures financial
convertible note payable financial
intercompany transactions financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Record quarterly clinic revenues supported by both organic growth and acquisitions
Seventh consecutive quarter of positive Clinic-Level Adjusted EBITDA
Balance sheet continues to improve following debt repayments
SARASOTA, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility”, “INVO”, or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the third quarter ended September 30, 2026.
Q3 2026 Financial Highlights (all metrics compared to Q3 2025 unless otherwise noted)
- Revenue increased
26% to$2,222,656 from$1,757,094 . - Consolidated clinic revenue increased
28% to$2,207,587 from$1,722,223 . - Net loss narrowed to
$2.1 million from$3.4 million . Loss from operations improved to$1.5 million from$1.6 million . - Clinic-Level Adjusted EBITDA before corporate operating and public company expenses remained positive for the seventh consecutive quarter.
- Consolidated Adjusted EBITDA was
$(1.0) million , compared to$(0.9) million in Q3 2025. - Cash was
$3.7 million at September 30, 2026, or approximately$3.10 per share. - As of November 13, 2026, the Company had 1,192,860 shares of common stock outstanding.
- Further strengthening of the balance sheet compared to December 31, 2025 with assets increasing by
$5.3 million , liabilities reduced by$5.5 million , and net equity of$18.0 million , or$15.09 per share.
Recent Highlights
- Organic and acquired growth. Revenue grew at both the Wisconsin and Atlanta clinics as the practices continued their efforts to reach more patients. Management believes that Wisconsin’s entry into the Progyny network in the first quarter contributed to growth by expanding access for patients with Progyny coverage. The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each contributed a full quarter of revenue.
- Clinic efficiency. INVO has implemented, and continues to evaluate, new tools to reduce time spent on documentation and administrative work across its practices, drawing on industry best practice. These initiatives are expected to continue driving improved patient experience and clinic-level efficiencies.
- Positive industry feedback at ASRM. In October 2026, INVO attended the American Society for Reproductive Medicine Scientific Congress & Expo in Baltimore, resulting in further expansion of potential acquisition opportunities.
- Improved balance sheet. INVO ended September with
$3.7 million in cash and$4.5 million in current liabilities, down from$10.3 million in current liabilities at year-end 2025. - Planned investment in Birmingham. In June 2026, INVO acquired the remaining
50% interest in its Birmingham clinic for an agreed purchase price of$175,001 payable to the sellers. The purchase price reflected the investments INVO expected to make under full ownership, including recruiting a new physician and adding key services, and the temporary revenue disruption as the new physician ramps up. - Continued clinic-level profitability. The clinic network generated approximately
$292,000 in Clinic-Level Adjusted EBITDA, its seventh consecutive positive quarter, after accounting for the approximate$193,000 impact in Q3 of the planned Birmingham acquisition transitioning.
Management Commentary
“Revenue grew again this quarter, and our clinics continued to generate positive Adjusted EBITDA before corporate expenses,” said Steve Shum, Chief Executive Officer of INVO Fertility. “We saw growth at our Wisconsin and Atlanta practices alongside the contribution from our acquisitions of the Indiana clinic and Birmingham clinic. That combination is what we set out to achieve by investing in our existing clinics and acquiring established practices.”
“We continue to see increased opportunities for acquisitions, which remain a key component to our growth objectives, as independent fertility practices look for ways to serve more patients while preserving the local relationships that patients and physicians value. As a publicly traded fertility clinic operator, INVO provides public market investors an alternative way to participate directly in that evolution and share in the potential growth of our clinic network. Equally important, we have purposely made key investments in people and additional infrastructure, in advance, in preparation to expand our network. We believe we have assembled an excellent team capable of executing on our growth plans and we look forward to leveraging our infrastructure as we expand and driving further operating performance.”
“Our balance sheet has also further strengthened in the period following the Wisconsin acquisition payment and the reduction in our current liabilities. We’re also focused on helping our clinics reach more patients and giving our clinical teams better tools and resources. Overall, the progress we’ve made and the opportunities we see on both sides of our growth strategy give us good reason to be excited about what comes next,” Shum concluded.
Third Quarter Financial Discussion
Revenue increased to approximately
Cost of services was approximately
Loss from operations improved to approximately
Consolidated Adjusted EBITDA was
Clinic-Level Adjusted EBITDA was
At September 30, 2026, cash totaled approximately
Clinic-Level Adjusted EBITDA
Clinic-Level Adjusted EBITDA was
Management is focused on growing this contribution through higher patient volumes, expanded services, and improved operating execution, while also adding (via its acquisition efforts) established, profitable clinics that can increase scale and allow corporate operating expenses to be supported across a larger revenue and earnings base.
(Unaudited, in dollars, before corporate operating and public company expenses)
| Fertility Clinic Services Segment | Q3 2026 | Q3 2025 |
| Clinic revenue | ||
| Operating expenses | 2,144,678 | 1,592,534 |
| Segment profit | 62,909 | 129,689 |
| Depreciation and amortization | 36,273 | 113,431 |
| Birmingham clinic – acquisition transition | 192,932 | - |
| Clinic-Level Adjusted EBITDA | $292,114 | $243,120 |
Clinic-Level Adjusted EBITDA is a non-GAAP measure. See Use of Non-GAAP Measures and the reconciliation below. Fertility Clinic Services Segment data derived from Note 15 – Segment Reporting in the Company’s third quarter 10-Q
Webcast
INVO Fertility will host a webcast to discuss its third quarter 2026 financial results and provide a business update.
Date and time: Monday, November 16, 2026, at 11:00 a.m. Eastern Time
Webcast registration: https://app.webinar.net/2WBLVyGJEq9
Replay: https://app.webinar.net/2WBLVyGJEq9
Use of Non-GAAP Measure
Included in this press release are references to Adjusted EBITDA and Clinic-Level Adjusted EBITDA, which are non-GAAP financial measures. These measures are not intended to be substitutes for financial measures reported in accordance with U.S. generally accepted accounting principles. Management believes that, when considered together with the GAAP figures, these measures provide meaningful information regarding operating performance, the earnings contribution of the Company’s clinic platform and trends in the business.
Clinic-Level Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations before corporate operating expenses, as calculated by management. This measure is intended to provide visibility into the performance and earnings capacity of the operating clinic platform separately from the costs associated with managing a public company and building a larger acquisition platform. Adjusted EBITDA and Clinic-Level Adjusted EBITDA may be calculated differently by INVO Fertility than by other companies that disclose measures with the same or similar terms.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements regarding organic growth initiatives, acquisition opportunities, integration of acquired clinics, balance sheet improvements, liquidity, the growth of our clinic platform and our ability to achieve cash flow break even or profitability, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
| INVO FERTILITY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Clinic revenue | $ | 2,207,587 | $ | 1,722,223 | $ | 6,357,605 | $ | 5,175,870 | ||||||||
| Product revenue | 15,069 | 34,871 | 55,761 | 82,063 | ||||||||||||
| Total revenue | 2,222,656 | 1,757,094 | 6,413,366 | 5,257,933 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of services | 1,436,870 | 1,121,174 | 4,071,782 | 3,252,659 | ||||||||||||
| Cost of goods sold | 14,144 | 6,575 | 79,443 | 13,622 | ||||||||||||
| Selling, general, and administrative expenses | 2,071,438 | 2,128,088 | 6,154,287 | 5,878,459 | ||||||||||||
| Impairment loss | - | - | - | 1,397,353 | ||||||||||||
| Depreciation and amortization | 177,564 | 136,741 | 465,835 | 540,940 | ||||||||||||
| Total operating expenses | 3,700,016 | 3,392,578 | 10,771,347 | 11,083,033 | ||||||||||||
| Loss from operations | (1,477,360 | ) | (1,635,484 | ) | (4,357,981 | ) | (5,825,100 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Gain from equity method joint ventures | - | 12,827 | 15,014 | 8,012 | ||||||||||||
| Gain on remeasurement | - | - | 2,452,032 | - | ||||||||||||
| Gain (loss) on change in fair value of derivatives | (562,997 | ) | (33,566 | ) | (4,353,222 | ) | 1,626,594 | |||||||||
| Loss on debt extinguishment | - | (1,416,610 | ) | (172,621 | ) | (2,108,880 | ) | |||||||||
| Gain on settlement | - | - | - | 939,500 | ||||||||||||
| Interest income | 74,735 | - | 214,249 | - | ||||||||||||
| Interest expense | (154,768 | ) | (322,765 | ) | (512,318 | ) | (1,071,200 | ) | ||||||||
| Total other income (expense) | (643,030 | ) | (1,760,114 | ) | (2,356,866 | ) | (605,974 | ) | ||||||||
| Net loss from continuing operations before income taxes | (2,120,390 | ) | (3,395,598 | ) | (6,714,847 | ) | (6,431,074 | ) | ||||||||
| Provision for income taxes | 29,530 | - | 85,684 | - | ||||||||||||
| Net loss from continuing operations | (2,149,920 | ) | (3,395,598 | ) | (6,800,531 | ) | (6,431,074 | ) | ||||||||
| Discontinued operations (Note 5) | ||||||||||||||||
| Loss on disposal of NTI | - | - | - | (1,534,517 | ) | |||||||||||
| Loss on discontinued operations of NTI | - | - | - | (16,452,562 | ) | |||||||||||
| Net loss | $ | (2,149,920 | ) | $ | (3,395,598 | ) | $ | (6,800,531 | ) | $ | (24,418,153 | ) | ||||
| Net Loss from continuing operations per share | ||||||||||||||||
| Basic | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (722.84 | ) | ||||
| Diluted | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (722.84 | ) | ||||
| Loss from discontinued operations per common share | ||||||||||||||||
| Basic | $ | - | $ | - | $ | - | $ | (2,021.70 | ) | |||||||
| Diluted | $ | - | $ | - | $ | - | $ | (2,021.70 | ) | |||||||
| Net Loss per common share: | ||||||||||||||||
| Basic | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (2,744.54 | ) | ||||
| Diluted | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (2,744.54 | ) | ||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | 880,233 | 21,569 | 607,101 | 8,897 | ||||||||||||
| Diluted | 880,233 | 21,569 | 607,101 | 8,897 | ||||||||||||
| INVO FERTILITY, INC. CONSOLIDATED BALANCE SHEETS | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 3,695,770 | $ | 2,077,842 | ||||
| Accounts receivable, net of allowances of | 170,423 | 217,263 | ||||||
| Inventory, net of allowances of | 230,806 | 225,253 | ||||||
| Prepaid expenses and other current assets | 347,840 | 241,145 | ||||||
| Total current assets | 4,444,839 | 2,761,503 | ||||||
| Property and equipment, net | 814,175 | 386,165 | ||||||
| Lease right of use | 2,052,056 | 1,286,217 | ||||||
| Intangible assets, net | 1,245,345 | 1,325,145 | ||||||
| Goodwill | 9,236,642 | 5,878,986 | ||||||
| Investment in NAYA Therapeutics | 2,466,810 | 2,466,810 | ||||||
| Note receivable – NAYA Therapeutics | 5,240,333 | 5,029,770 | ||||||
| Note receivable – HRCFG | - | 1,085,528 | ||||||
| Total assets | $ | 25,500,200 | $ | 20,220,124 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 1,297,870 | $ | 2,034,057 | ||||
| Accrued compensation | 377,110 | 285,946 | ||||||
| Notes payable - current portion, net | 577,108 | 394,664 | ||||||
| Convertible note payable - related party, net | 17,882 | 880,000 | ||||||
| Deferred revenue | 728,630 | 721,897 | ||||||
| Lease liability, current portion | 413,117 | 208,987 | ||||||
| Additional payments for acquisitions, current portion | 998,000 | 3,925,000 | ||||||
| Warrant liability | - | 1,881,078 | ||||||
| Other current liabilities | 47,812 | - | ||||||
| Total current liabilities | 4,457,529 | 10,331,629 | ||||||
| Lease liability, net of current portion | 1,769,838 | 1,171,075 | ||||||
| Liability for excess losses of equity method investee | - | 448,474 | ||||||
| Notes payable – net of current portion | 362,445 | 744,725 | ||||||
| Derivative liability | 745,288 | - | ||||||
| Deferred tax liability | 80,159 | - | ||||||
| Other liabilities, net of current portion | 79,688 | - | ||||||
| Additional payments for acquisition, net of current portion | - | 300,000 | ||||||
| Total liabilities | $ | 7,494,947 | $ | 12,995,903 | ||||
| Stockholders’ equity | ||||||||
| Series C-2 Preferred Stock, | $ | - | $ | 2,406,359 | ||||
| Series D Preferred Stock, | 400,000 | - | ||||||
| Common Stock, $.0001 par value; 62,500,000 shares authorized; 1,192,860 and 119,358 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 119 | 11 | ||||||
| Additional paid-in capital | 115,790,672 | 96,187,254 | ||||||
| Accumulated deficit | (98,185,538 | ) | (91,369,403 | ) | ||||
| Total stockholders’ equity | 18,005,253 | 7,224,221 | ||||||
| Total liabilities and stockholders’ equity | $ | 25,500,200 | $ | 20,220,124 | ||||
| Adjusted EBITDA | ||||||||
| For the Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net loss from continuing operations | $ | (2,149,920 | ) | $ | (3,395,598 | ) | ||
| Interest expense | 154,768 | 322,765 | ||||||
| Interest income | 74,735 | - | ||||||
| Tax expense | 29,530 | - | ||||||
| Depreciation and amortization | 177,564 | 136,741 | ||||||
| Stock-based compensation | 188,622 | 493,348 | ||||||
| Non cash compensation for services | - | 45,000 | ||||||
| Gain on remeasurement | - | - | ||||||
| Gain on change in fair value of warrant liability | 562,997 | 33,566 | ||||||
| Loss from debt extinguishment | - | 1,416,610 | ||||||
| Adjusted EBITDA | $ | (961,704 | ) | $ | (947,568 | ) | ||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did INVO Fertility revenue grow in the third quarter of 2026?
INVO Fertility's third-quarter revenue increased 26% to $2,222,656 from $1,757,094 a year earlier. Clinic revenue increased 28% to $2,207,587, supported by growth in Wisconsin and Atlanta and contributions from the acquired Indiana and Birmingham clinics.
Was INVO Fertility profitable in the third quarter of 2026?
INVO Fertility recorded a $2,149,920 net loss, despite positive Clinic-Level Adjusted EBITDA of $292,114. That non-GAAP clinic measure excludes corporate operating and public-company expenses and includes a $192,932 Birmingham transition add-back. Consolidated Adjusted EBITDA was negative $1.0 million.